Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies

Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings

GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus

Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program

Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC

Lupin appoints Claus Jepsen as President, Global Specialty

Pradhan Mantri Bhartiya Janaushadhi Pariyojana achieves sales worth Rs. 1,000 croe in Oct. 2024

Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups

Senores Pharmaceuticals gets SEBI nod for IPO

The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension